Literature DB >> 12850926

A prospective quality of life study in patients with locally advanced prostate cancer, treated with radiotherapy with or without regional or interstitial hyperthermia.

M Van Vulpen1, J R J De Leeuw, M P R Van Gellekom, J Van Der Hoeven, A De Graeff, R J A Van Moorselaar, I Van Der Tweel, P Hofman, J J W Lagendijk, J J Battermann.   

Abstract

INTRODUCTION: The aim of this prospective study was to describe quality of life (QoL) in patients with locally advanced prostate carcinoma treated with conventional radiotherapy and to evaluate the influence of adding regional or interstitial hyperthermia.
MATERIALS AND METHODS: All patients were irradiated using a CT-planned conventional three field technique, administering 70 Gy to prostate and vesicles. In two different phase I studies, hyperthermia was added to the radiotherapy. Twelve patients were treated with one interstitial hyperthermia treatment, lasting 60 min. Fourteen patients have been treated with five regional hyperthermia treatments, lasting 75 min each. In both hyperthermia studies, the body, bladder and rectum temperatures remained below safety limits. Patients treated with radiotherapy alone (n = 58) or combined with regional (n = 8) or interstitial hyperthermia (n = 12) completed the European Organization for Research and Treatment of Cancer (EORTC) core questionnaire (C30 + 3), the EORTC prostate cancer module (PR25) and the Rand 36 health survey before treatment and 1 and 6 months after completion of treatment. Analysis of Variance (ANOVA) for repeated measurements has been performed to describe the data.
RESULTS: All patient groups were comparable concerning patient characteristics. No significant interaction or difference in QoL has been noticed between the two hyperthermia patient groups and the patient group without hyperthermia. Therefore, all groups were analysed together (n = 78) to detect QoL changes in time. A deterioration of QoL has been measured from baseline to 1 month after treatment. Fatigue, pain, urinary symptoms, bowel symptoms and financial difficulties increased significantly. Social, physical and role functioning worsened significantly. No differences in QoL were measured 6 months after treatment compared to the baseline measurement, except for a decrease in sexual activity.
CONCLUSIONS: After radiotherapy with or without hyperthermia only a temporary deterioration of QoL occurs, concerning social, psychological and disease related symptoms. Additional hyperthermia does not seem to decrease QoL.

Entities:  

Mesh:

Year:  2003        PMID: 12850926     DOI: 10.1080/0265673031000063855

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN: 0265-6736            Impact factor:   3.914


  6 in total

1.  Mild hyperthermia as a localized radiosensitizer for deep-seated tumors: investigation in an orthotopic prostate cancer model in mice.

Authors:  Justin Cohen; Akbar Anvari; Santanu Samanta; Yannick Poirier; Sandrine Soman; Allen Alexander; Maida Ranjbar; Ramilda Pavlovic; Andrew Zodda; Isabel L Jackson; Javed Mahmood; Zeljko Vujaskovic; Amit Sawant
Journal:  Br J Radiol       Date:  2019-02-12       Impact factor: 3.039

2.  Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer: long-term results from Dana-Farber Cancer Institute study 94-153.

Authors:  Mark D Hurwitz; Jorgen L Hansen; Savina Prokopios-Davos; Judith Manola; Qian Wang; Bruce A Bornstein; Kullervo Hynynen; Irving D Kaplan
Journal:  Cancer       Date:  2010-09-30       Impact factor: 6.860

3.  Interstitial hyperthermia of the prostate in combination with brachytherapy : An evaluation of feasibility and early tolerance.

Authors:  A M Kukiełka; M Hetnał; P Brandys; T Walasek; T Dąbrowski; E Pluta; D Nahajowski; R Kudzia
Journal:  Strahlenther Onkol       Date:  2013-04-20       Impact factor: 3.621

4.  Evaluation of the effect of hyperthermia and electron radiation on prostate cancer stem cells.

Authors:  Zhila Rajaee; Samideh Khoei; Seied Rabi Mahdavi; Marzieh Ebrahimi; Sakine Shirvalilou; Alireza Mahdavian
Journal:  Radiat Environ Biophys       Date:  2018-02-17       Impact factor: 1.925

Review 5.  Integrating Hyperthermia into Modern Radiation Oncology: What Evidence Is Necessary?

Authors:  Jan C Peeken; Peter Vaupel; Stephanie E Combs
Journal:  Front Oncol       Date:  2017-06-30       Impact factor: 6.244

6.  Regional hyperthermia and moderately dose-escalated salvage radiotherapy for recurrent prostate cancer. Protocol of a phase II trial.

Authors:  Arndt-Christian Müller; Daniel Zips; Vanessa Heinrich; Ulf Lamprecht; Otilia Voigt; Susen Burock; Volker Budach; Peter Wust; Pirus Ghadjar
Journal:  Radiat Oncol       Date:  2015-07-08       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.